800 results about "Immune reaction" patented technology

The invention discloses recombinant human XVII type collagen as well as a preparation method and application thereof. The recombinant human XVII type collagen is obtained by repeating an amino acid sequence from natural human XVII type collagen. The amino acid sequence of the recombinant human XVII type collagen is derived from natural human XVII type collagen, and the recombinant human XVII type collagen does not generate adverse immune response when being used for a human body. The recombinant human XVII type collagen can be secreted and expressed in a commercial yeast expression system, the expression quantity is greater than 10g / L, the preparation method is simple, and the high-yield recombinant human XVII type collagen can be obtained at low cost; in addition, the cell adhesion promoting activity of the recombinant human XVII type collagen is obviously superior to that of human collagen.

The invention discloses a nano system for tumor radioimmunotherapy and a preparation method and application thereof, and belongs to the technical field of biological medicines.The system modifies bacteria outer membrane vesicles (OMVs) through engineering to enable the bacteria outer membrane vesicles to carry magnetite nanoparticles (Fe3O4NPs) and an ATR inhibitor VE822, the Fenton reaction activity of the Fe3O4NPs and the synergistic effect of the ATR inhibitor for inhibiting DNA damage repair are utilized, and the tumor radioimmunotherapy effect is improved. DNA damage is amplified, DNA damage reaction (DDR) is inhibited, generation of hydroxyl radicals (. OH) under radiation is enhanced, radiation resistance of tumor cells is reduced, immune reaction is reactivated, infiltration of effector T cells to tumors is improved, growth of mice tumors is remarkably inhibited, and an effective strategy is provided for tumor radioimmunotherapy.

The invention relates to the technical field of biological information, in particular to an immunoreaction evaluation method based on tumor neoantigen activity sorting. The method comprises the following steps: obtaining genome data of tumor and normal tissues through whole exon sequencing, extracting multi-dimensional features of candidate somatic mutation, and screening by combining a Gaussian mixture model and a Transform model to obtain a high-confidence mutation genome set; predicting the HLA genotype of a patient based on sequencing data, translating and mutating into a peptide fragment, predicting the binding affinity of the peptide fragment and an MHC molecule by using an XGBoost model, and calculating a new antigen activity score sequence in combination with various parameters; and finally, synthesizing a new antigen peptide fragment according to a sorting result, carrying out in-vitro co-culture to detect an IFN-gamma secretion result, and dynamically optimizing a characteristic combination coefficient through a PPO algorithm to realize intelligent iterative updating, so that the accuracy of new antigen screening and the immunoreaction prediction capability are remarkably improved.

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field energy to target tissue areas in a specific dose so as to obtain a superior outcome. The specialized PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. The specialized PEF energy provides superior outcomes to radiofrequency ablation and irreversible electroporation.

The invention relates to the technical field of bioengineering, in particular to a recombinant VII type collagen for inhibiting scars as well as a preparation method and application of the recombinant VII type collagen. The amino acid sequence of the recombinant VII type collagen is as shown in SEQ ID NO. 1. The recombinant VII type collagen provided by the invention has a better cell adhesion function, so that the recombinant VII type collagen can be applied to the fields of preparation of tissue materials, wound dressings and the like. Meanwhile, the VII type collagen does not contain any tag or exogenous amino acid sequence, is a completely humanized sequence, and does not generate immune response. The VII type collagen has a good adhesion effect, the adhesion effect is better than that of other recombinant collagen, the adhesion effect is equivalent to that of a common cell adhesive in the market, scars can be reduced by inhibiting activation of a TGF-beta pathway, and the VII type collagen can be developed into skin care products and medical instruments for promoting traceless wound repair and has a wide application prospect.

The invention discloses a micro-plastic integrated intelligent detection device, which comprises: a sample pretreatment module, which comprises a sample mixing module, a filtering separation module, an enrichment concentration module and a surface modification and marking module which are communicated in sequence and is used for mixing, filtering, enriching, modifying and marking a sample in sequence; the immunoreaction module is used for performing immunoreaction on the sample and the anti-polystyrene monoclonal antibody freeze-dried product marked by the quantum dot fluorescent microspheres; the fluorescence detection module is used for carrying out fluorescence detection on the test strip subjected to the immune reaction; the automatic control module is electrically connected with the sample pretreatment module, the immunoreaction module and the fluorescence detection module and is used for controlling the operation of each module. According to the invention, the sample processing module, the reaction module, the detection module and the control module are in close cooperation, the sample enters each module in sequence after simple pretreatment, detection and result output are semi-automatically completed, frequent manual operation of different instruments is not needed, the operation steps and time are reduced, and the operation difficulty is reduced.

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

Provided are methods, compositions, and kits for improving a delivery of a nucleic acid to a cell in an organ of a subject. Such methods, compositions, and kits may include a sonoactive agent and a nucleic acid comprising a cargo polynucleotide and a nuclear localization element and / or an innate immune response avoidance moiety, which may be an aptamer. Delivery may involve sonoporation.

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.

Drug delivery nanoparticle compositions and methods for the treatment of a cancer are provided that can be used individually or in combination. These compositions and methods include: (1) exogenous vaccination using neoantigens or tumor-associated antigens to potentiate an anti-tumor immune response; (2) nanoparticle-based drug delivery targeting the liver, aimed at reprogramming the hepatic immune environment to reduce or eliminate tumor antigen tolerance, thereby enhancing the immune system's ability to combat metastatic cancer; and (3) expansion of the liver metastasis treatment platform to target tumor-associated lymphoid structures, supporting the immune response at the primary tumor site. Any of these methods may be optionally combined with chemo-immunotherapy for enhanced efficacy.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

Provided herein are SARS-CoV-2 virus-like particles as well as methods and compositions for generating SARS-CoV-2 virus-like particles. The SARS-CoV-2 virus-like particles can load and deliver transcripts (including engineered transcripts that can include therapeutic agents) into cells expressing SARS-CoV-2 entry factors. The SARS-CoV-2 virus-like particles are also useful for detecting immune response in antibodies from subjects.

Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

The invention relates to the technical field of virology, immunology and biomedicine, in particular to a human metapneumovirus F protein mutant and application thereof. The human metapneumovirus F protein mutant provided by the invention has stable prefusion conformation and high expression quantity, and can form a stable trimer, so that the human metapneumovirus F protein mutant can be used for HMPV vaccine development. The F protein mutant provided by the invention has excellent immunogenicity, and can induce excellent immune response when being used together with an HA201 composite adjuvant (QS21 + MPL liposome).

The invention discloses an establishment method and a verification method of a hydrogen peroxide induced mouse autism model, and relates to the technical field of medical biologication.The establishment method of the hydrogen peroxide induced mouse autism model comprises the following steps that a hydrogen peroxide solution is injected into the abdominal cavity of a pregnant mouse, hydrogen peroxide induction is conducted, and the mouse autism model is obtained. And obtaining a hydrogen peroxide induced offspring mouse, namely the mouse autism model. Hydrogen peroxide is used for near intraperitoneal injection of a female mouse during pregnancy, the oxidative stress state of the female mouse during pregnancy and the oxidative stress state of an offspring mouse embryo are induced through independent hydrogen peroxide, and obvious immune response of the female mouse is not caused, so that an ASD mouse model specifically induced by oxidative stress is formed; the obtained ASD offspring mouse has a remarkable ASD phenotype, but does not show obvious dyskinetic disorder.

The invention relates to the technical field of antibody detection methods, in particular to a diagnosis method and a detection system based on autoimmune disease antibody detection, and the method comprises the following steps: S1, an analysis module obtains electrochemistry related information and light reflection related information through electrochemical analysis and light reflection analysis; related information of electrochemistry and related information of light reflection are transmitted to the control module; s2, the control module obtains an antibody concentration index according to the electrochemistry related information and the light reflection related information, and transmits the antibody concentration index to a diagnosis module; s3, the diagnosis module obtains strong or weak immunoreaction information according to the antibody concentration index, and transmits the strong or weak immunoreaction information to the communication module; and S4, the communication module transmits strong or weak immunoreaction information to the user side. Immunoassay is combined with electrochemical analysis and light reflection analysis for detection, and the accuracy and comprehensiveness of detection can be improved by analyzing in different directions and combining results.

The invention discloses a double-channel gold-copper-doped graphene electrochemical immunosensor as well as a preparation method and application thereof. The double-channel gold-copper-doped graphene electrochemical immunosensor comprises a gold / gold-copper co-doped vertical graphene electrode, and bovine serum albumin and an antibody which are incubated on the gold / gold-copper co-doped vertical graphene electrode, the gold / gold-copper co-doped vertical graphene electrode comprises a gold-copper co-doped vertical graphene electrode and gold nanoparticles loaded on the surface of the gold-copper co-doped vertical graphene electrode, and the gold-copper co-doped vertical graphene electrode comprises a substrate and a gold-copper co-doped vertical graphene nanosheet grown on the surface of the substrate. The sensor capable of sensitively detecting the concentration of the carcinoembryonic antigen secreted by the tumor cells is prepared, an immunoreaction detection system is built, a reliable industrial signal amplification platform is provided for early diagnosis of tumors, and a new strategy is developed for research of tumor cytology.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The present invention relates to an antibody specific for Staphylococcus aureus protein A, and to a composition or kit comprising same for detecting Staphylococcus aureus or diagnosing skin conditions. The monoclonal antibody according to the present invention is highly reactive to antigens, and, particularly, can detect antigens rapidly and accurately even at low concentrations due to two antibodies of different CDRs having been combined and used as capture and detection antibodies, thus allowing the monoclonal antibody to be used in rapid self-diagnostic kits and the like. In using the monoclonal antibody, the degree of proliferation of Staphylococcus aureus on the skin surface and the like can be visually checked, abnormal states of the skin, such as inflammation and excessive immune response, can be diagnosed, incidence probability and persistence of related diseases can be predicted, and subsequent treatment methods can be determined.

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knocking out the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising a recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or vaccine composition can be used in a method against an immune response initiated by Mycobacterium tuberculosis. The invention also relates to a method for obtaining the recombinant bovine mycobacterium BCG strain.

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011 / 0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

Methods for interfering or controlling IFN induction, IFN production and / or IFN activity are disclosed, harnessing viral mechanisms for evading or suppressing host anti-viral immune reactions. These methods comprise administration of one or more viral messenger RNAs (mRNAs) coding for proteins or peptides that control or interfere with signal transduction upstream and / or downstream of IFN induction, thereby providing a means for preventing or treating diseases, disorders or conditions associated with increased IFN production, such as cancer, autoimmune diseases, inflammatory diseases and interferonopathies.

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.

The invention discloses a YOLO-Drop-based 3D printing droplet microfluidic immunoassay method, which organically integrates a high-precision microfluidic chip preparation technology, a droplet-level immunoreaction system and a fluorescence imaging acquisition and deep learning detection algorithm. And full-chain closed-loop processing from droplet generation, fluorescence signal acquisition, image recognition, result statistics to concentration quantitative analysis is realized. Through deep combination of chip physical parameters and model input features, the method not only significantly improves the accuracy and stability of droplet identification and concentration quantification, but also enhances the robustness of the algorithm under complex sample conditions through multi-scale feature fusion and a signal dual screening mechanism. Meanwhile, the optimized YOLO-Drop model supports embedded efficient reasoning, so that the whole analysis process has the characteristics of real-time performance and high throughput, and the method is suitable for rapid quantitative detection of various biomarkers.

Provided herein are methods for one or more of a) modulating an immune response to a tumor cell in a patient, b) treating cancer in a cancer patient; or c) eliciting an anti-tumor response in a patient, comprising modulating the expression or activity of Junction Adhesion Molecule Like (JAML).

A pool of peptides comprising a first peptide and a second peptide, wherein: (i) the first peptide is from 9 to 40 amino acids in length and comprises at least 9 contiguous amino acids of the sequence

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.